Algernon Pharmaceuticals Inc.

AGN

CA01559R4008

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 09:54:10 2024-05-21 am EDT			5-day change	1st Jan Change
0.155 ^CAD	+10.71%		+29.17%	+138.46%

Apr. 30	Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
Apr. 10	Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	CI

Algernon Pharmaceuticals Appoints Mark Swaim to its Medical and Scientific Advisory Board

October 09, 2020 at 08:00 am EDT

Algernon Pharmaceuticals Inc. announced that Dr. Mark Swaim, a former practicing physician and researcher has joined the Algernon Medical and Scientific Advisory Board.

Latest news about Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 29	CI
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	Apr. 09	CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding	Apr. 02	CI
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset	Apr. 01	CI
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	Mar. 27	MT
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.	Mar. 26	CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	Jan. 31	MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 25	CI
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	Jan. 24	CI
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	Jan. 11	MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Dec. 29	CI
Algernon Pharmaceuticals Increased Private Placement	Dec. 27	MT
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding	Dec. 26	CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding	Dec. 11	CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast	Nov. 30	MT
Algernon Pharmaceuticals Brief: Says Received Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD	Nov. 30	MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD	Nov. 30	CI
Algernon Pharma in LOI For Acquisition of its Chronic Cough Research Program For US$2 Million and 20% Equity Stake	Nov. 22	MT
Algernon Pharmaceuticals Brief: Announcing LOI for Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for US$2 Million and a 20% Equity Position	Nov. 22	MT
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH	23-09-06	MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-28	CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding	23-07-13	CI
Algernon Pharmaceuticals Engages Maxim Group to Provide Financial Advisory and Investment Banking Services, and to Assist in Identifying and Evaluating Potential M&A and Strategic Opportunities	23-06-27	CI
Algernon Pharmaceuticals Engage Maxim Group to Explore Spin-Off of Ifenprodil Phase 2 Chronic Cough Drug Development Program	23-06-27	MT
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference	23-06-06	MT

Chart Algernon Pharmaceuticals Inc.

Duration

Period

More charts

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Companyâs lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Psychedelic Research Interdisciplinary Conference

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALGERNON PHARMACEUTICALS INC.	+138.46%	2.25M
VERTEX PHARMACEUTICALS INCORPORATED	+9.62%	115B
REGENERON PHARMACEUTICALS, INC.	+13.22%	107B
BIONTECH SE	-13.40%	22.31B
ARGENX SE	-3.49%	21.6B
BEIGENE, LTD.	-5.71%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.91%	14.26B
SAREPTA THERAPEUTICS, INC.	+34.43%	12.37B
LEGEND BIOTECH CORPORATION	-26.76%	8.28B

Bio Therapeutic Drugs

Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Biotechnology & Medical Research

Algernon Pharmaceuticals Appoints Mark Swaim to its Medical and Scientific Advisory Board

Latest news about Algernon Pharmaceuticals Inc.

Chart Algernon Pharmaceuticals Inc.

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs